Clinical Indication ID & Name
Thyroid Follicular Carcinoma
Test Group
Solid Tumours (Adult)
Specialties
Test code
M10.1
Test name
Multi-target NGS panel - small variant (KRAS, NRAS, HRAS)
Target genes
KRAS, NRAS, HRAS
Test scope
Small variant detection
Test method/ technology
Panel
Optimal Family Structure
n/a
Eligibility Criteria
Molecular assessment will aid diagnosis or management
Test code
M10.2
Test name
Multi-target NGS panel - structural variant (NTRK1, NTRK2, NTRK3, RET)
Target genes
NTRK1, NTRK2, NTRK3, RET
Test scope
Structural variant detection
Test method/ technology
Panel
Optimal Family Structure
n/a
Eligibility Criteria
Molecular assessment will aid therapy choice
Commissioning group
n/a
Overlapping idications
n/a
Address for samples/request forms
Cancer Genetics
Genetics Laboratories
5th Floor Tower Wing
Guy’s Hospital
Great Maze Pond
London
SE1 9RT
Contact with queries
Supporting documents
n/a
Education resources
n/a
Turn around times
All our turnaround times are listed on our specific turn around page https://southeastgenomics.nhs.uk/professionals/service-turn-around-times/
Request form download
Consent record
See consent guidance in test request form
Sample requirements
Sample Requirements Each sample must be sent labelled with 3 patient identifiers and must state the sample type clearly on the sample container. Sample Rejection Samples may be rejected for the following reasons: 1. Samples and request form do not show at least three identical patient identifiers 2. The sample is in the incorrect collection media 3. The request form is not sufficiently completed 4. The sample is not of sufficient volume 5. The sample is too old|Sample Storage and Volume Required: The GLH does not have microtome sectioning capabilities, and therefore whole paraffin blocks are not accepted. The GLH can receive samples in the following formats: 1. Curls/scrolls: If the tumour cellularity of the whole section is >20% curls/scrolls of paraffin sections are acceptable. Please send in a sealed single-use microtube, either 1.5ml or 2ml. Ideally 5 sections of 10micron thickness should be submitted. Please do not send curls with an overall tumour cellularity of <20%; see section 2. 2. Slides: 5 sections of 10 micron thickness on uncharged unstained glass slides are required. The slides must be clearly labelled with the sample histology number and patient surname. An H&E section at 4micron should be submitted with the unstained sections – this can be the diagnostic H&E or an additional slide cut at the same time as the unstained sections. This slide should be submitted with the USS and the request form . The area of the tumour must be outlined on the H&E section with a permanent marker pen: this will allow microdissection if necessary. The marked H&E slide and FFPE unstained slides must have the histology number and patient surname clearly marked on the slides and must correspond to that on the request form. Sections should be dried prior to transfer to the hub lab. Sections must NOT be baked onto slides. Please note that spare unstained slides sectioned previously should not be used for molecular analyses. All slides or microtubes should be labelled with the laboratory histology number and patient surname. Unstained slides should be air-dried before packaging for dispatch. As RNA integrity from FFPE sections has been observed to decrease over time when exposed to light and air, air-dried sections intended for RNA analysis may benefit from storage in a fridge if not dispatched promptly. Samples that are referred for MLH1 promoter hypermethlyation as part of the Lynch pathway require a matched normal control sample to run alongside the tumour sample; please send 5ml blood in EDTA. If it is not possible to obtain a blood sample from the patient, please send material from one normal tissue block in addition to the material from the tumour block as either curls or slides as described above. Storage, sample packing and transportation: The sample should be submitted together with the GLH request form fully completed. This must include the clinical details (tumour type and histological subtype), and a copy of the pathology report if authorised (the pathology report should not substitute completion of the clinical details on the referral form). The transport of the sample and documentation should be via either tracked Royal Mail or other recognised courier services. Patient/Clinician Instructions: All samples for submission for genomic testing must be assessed for tumour content. For NGS genomic analysis, a minimum tumour cellularity required is >20%. Assessment of tumour cellularity is performed by the reporting pathologist, who will have the histopathological expertise for the particular tumour specialty. The pathologist should select the most appropriate block from the specimen, which provides the highest tumour cellularity, as well as the most representative morphology of the tumour. Where there is tumour heterogeneity on morphological assessment, the tumour with the most invasive component or that which confers the worst prognosis should be selected. Based on above online guidance, the H&E slide for the block is assessed for: • The overall tumour cellularity (estimated to nearest 100 cells if <1000, nearest 1000 if <10000, or nearest 10000). • The percentage of numbers of tumour cells, as a total of all nucleated cells (including admixed inflammatory and stromal cells) rather than relative surface area of tumour on slide. This should be estimated to the nearest 10%. • This percentage should be adjusted for the 3-dimensional arrangement of cells, based on nuclear size/volume, such that a small cluster of lymphocytes will yield more DNA than the equivalent sized nest of tumour cells, in which each cell will be larger and deeper. The presence of tumour necrosis and melanin pigmentation (in melanoma specimens). If the tumour cellularity on the whole section is >20%, the entire section may be used for processing at the GLH (see below for the options). If the cellularity is <20%, another more appropriate block should be selected if available. Alternatively, the pathologist can mark on the H&E slide an area of tumour which will yield a tumour cellularity of >20%, a clear statement of the tumour cellularity in the marked area should be given on the referral form. This will allow the marked area of the sample to be selected for testing and macrodissected at the GLH. The tumour cellularity assessment of either the whole slide or the marked area selected for genomic analysis must be recorded in the test request form (Appendix B). Please ensure that the area of tumour cellularity referred to on the referral form is clear (either in marker area or as a whole section assessment). If it is not possible to identify any area on all the blocks which will yield tumour cellularity of >20%, this sample will not be suitable for genomic (NGS) analysis. However, for specific tumours, the sample can be tested using salvage analysis techniques. In this case, the pathologist should perform tumour cellularity assessment with/without marking a chosen area, recording the tumour cellularity as <20%. Factors affecting performance of test/interpretation of results: Pathology samples should be fixed, process and embedded as per routine laboratory protocols. For optimal DNA and RNA preservation, the sample must be fixed in 10% neutral buffered formalin within 1 hour after obtaining the sample. For large resection specimens, the sample must be sliced or opened to enable adequate penetration of formalin into the tissue. The tissue should be fixed for <48 hours, and not be fixed over the weekend where possible. Rapid processing may also have a detrimental effect on the quality of extracted nucleic acids and suitable alternative material sent, where possible. Sampling of the tissue for blocks prior to embedding should be done as per local protocols for diagnostic purposes. There is no requirement to sample extra material for genomic testing. Cytology samples are also accepted by the GLH. Cytology samples with diagnostic material should be made into a cell block according to local laboratory protocols and embedded in paraffin blocks as per histology specimens. To prevent wastage or loss of tissue for analysis, it is recommended that once the pathologist has made an initial assessment of the specimen and the sample is appropriate for genomic analysis, sections for submission to the GLH may be made, but without compromise to other tests (such as deeper levels or immunohistochemistry), which are required for making a histological diagnosis. This will be at the discretion of the reporting pathologist, but may include: preparation of sections immediately after cutting sections for other tests without trimming, or cutting unstained sections between levels of material. Please avoid excessive trimming or thick sections in the routine diagnostic setting. For preparation of the material for genomic analysis, the microtome blade should be cleaned with 70% IMS prior to cutting sections of each separate sample. Alternative methods of preventing contamination may also be used, including changing the microtome blade between sectioning each sample or the use of commercial agents (eg. DNA-away). This is to prevent cross-contamination of DNA/ RNA. It is not necessary to change the water in the water-bath, but the bath surface should be wiped with tissue paper. The uppermost section should be discarded at any new sectioning time-point and only subsequent sections collected.